Technetium (^99mTc) votumumab

Technetium (^99mTc) votumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	tumor antigen CTAA16.88
Clinical data
ATC code	V09IA04 (WHO) ;
Legal status
Legal status	not marketed;
Identifiers
CAS Number	148189-70-2 ;
ChemSpider	none;
	(what is this?) (verify)

Technetium (^99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m.^[1] It was developed for the detection of colorectal tumors, but has never been marketed.^[2]

The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.^[3]

References

^ WHO Drug Information
^ EMA: Public Statement on HumaSPECT Archived 2007-06-10 at the Wayback Machine
^ EMA: Summary of Product Characteristics for HumaSPECT

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] WHO Drug Information

[EMEA-2] EMA: Public Statement on HumaSPECT Archived 2007-06-10 at the Wayback Machine

[3] EMA: Summary of Product Characteristics for HumaSPECT

[1]

[2]

[3]